Comparing pevonedistat plus azacitidine versus azacitidine alone in patients with higher-risk MDS/CMML or low-blast AML

Bookmark and Share
Published: 11 Jun 2020
Views: 150
Rating:
Save
Prof Lionel Ades - Hôpital Saint-Louis, Paris, France

Prof Lionel Ades speaks to ecancer about a phase II study he presented at the ASCO 2020 virtual meeting, which investigated the combination of pevonedistat plus azacitidine versus azacitidine in patients with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukaemia (CMML), or low-blast acute myelogenous leukaemia (LB AML).

He describes the background of the study and outlines the design of the trial, which enrolled a total of 120 patients with higher-risk MDS/CMML or LB AML.

Prof Ades explains the results of the trial, which a trend towards longer event-free survival in the intent-to-treat population, with pevonedistat plus azacitidine - compared to azacitidine alone. The toxicity profile was also similar across the two groups of patients.

He notes that an additional randomised phase III trial is currently underway to evaluate the combination of pevonedistat plus azacitidine further.